Spots Global Cancer Trial Database for TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer
Official Title: Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer
Study ID: NCT00051948
Conditions
Interventions
Study Description
Brief Summary: This is a dose-ranging, open label, Phase 1-2a study of TLK286 in combination with Paraplatin (carboplatin) in patients with recurrent ovarian cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Santa Monica Hematology/Oncology Consultants, Santa Monica, California, United States
Midwest Cancer Research Group, Inc., Skokie, Illinois, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
M.D. Anderson Cancer Center, Houston, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
